← Back to Search

Cord Blood Units

Unlicensed CBU for Blood Cancers

N/A
Recruiting
Research Sponsored by Center for International Blood and Marrow Transplant Research
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up cord blood engraftment occurs in weeks following transplant is defined as defined as anc 500/mm3 and is analyzed at 100 days post-transplant.
Awards & highlights

Summary

This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.

Eligible Conditions
  • Blood Cancers
  • Inherited Metabolic Disorders
  • Histiocytic Disorders
  • Acute Myelogenous Leukemia
  • Acute Lymphoblastic Leukemia
  • Acute Leukemia
  • Leukemia
  • Myelodysplastic Syndrome / Myeloproliferative Neoplasms
  • Hodgkin's Lymphoma
  • Non-Hodgkin's Lymphoma
  • Multiple Myeloma
  • Hemolytic Anemia
  • Autoimmune Diseases
  • Aplastic Anemia
  • Thrombocytopenia
  • Immune Disorders

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~cord blood engraftment occurs in weeks following transplant is defined as defined as anc 500/mm3 and is analyzed at 100 days post-transplant.
This trial's timeline: 3 weeks for screening, Varies for treatment, and cord blood engraftment occurs in weeks following transplant is defined as defined as anc 500/mm3 and is analyzed at 100 days post-transplant. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Neutrophil recovery of ≥500/mm3 after cord blood transplantation

Trial Design

1Treatment groups
Experimental Treatment
Group I: Unlicensed CBUExperimental Treatment1 Intervention
The cohort includes recipients of any age receiving unlicensed cryopreserved cord blood units (CBUs) for designated indications.

Find a Location

Who is running the clinical trial?

National Marrow Donor ProgramOTHER
60 Previous Clinical Trials
102,561 Total Patients Enrolled
Center for International Blood and Marrow Transplant ResearchLead Sponsor
38 Previous Clinical Trials
200,093,431 Total Patients Enrolled
1 Trials studying Blood Cancers
99,999,999 Patients Enrolled for Blood Cancers
John Miller, MD, PhDStudy ChairNMDP/CIBMTR
~56666 spots leftby Oct 2041
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top